Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current Alzheimer Research

• Publication date

  2007-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/156720507781077313PMID 17627485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

  2006cited by this paper
• Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

  2006cited by this paper
• Butyrylcholinesterase attenuates amyloid fibril formation in vitro.

  2006cited by this paper
• Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease

  2006cited by this paper
• Everyday action in dementia: Evidence for differential deficits in Alzheimer's disease versus subcortical vascular dementia

  2006cited by this paper
• Subcortical vascular dementia

  2005cited by this paper
• Relationship between serum butyrylcholinesterase and the metabolic syndrome.

  2005cited by this paper
• Hallucinations and mortality in Alzheimer disease.

  2005cited by this paper
• The K Variant of the Butyrylcholinesterase Gene Is Associated with Reduced Phosphorylation of Tau in Dementia Patients

  2005cited by this paper
• Delusions and hallucinations are associated with worse outcome in Alzheimer disease.

  2005cited by this paper
• White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease.

  2005cited by this paper
• Frontal dysfunction contributes to the genesis of hallucinations in non‐demented Parkinsonian patients

  2005cited by this paper
• Efficacy and Safety of Donepezil in the Treatment of Executive Dysfunction in Parkinson Disease: A Pilot Study

  2005cited by this paper
• Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's Disease

  2005cited by this paper
• Benefits of rivastigmine on attention in dementia associated with Parkinson disease

  2005cited by this paper
• Absence of cholinergic deficits in “pure” vascular dementia

  2005cited by this paper
• Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.

  2005cited by this paper
• Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both

  2005cited by this paper
• The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs

  2005cited by this paper
• Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease?

  2005cited by this paper
• Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation

  2005cited by this paper
• Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia

  2005cited by this paper
• Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

  2005cited by this paper
• Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

  2005cited by this paper
• Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD

  2004cited by this paper
• Risk factors for geriatric depression: the importance of executive functioning within the vascular depression hypothesis.

  2004cited by this paper
• Lewy body-related alpha-synucleinopathy in the aged human brain.

  2004cited by this paper
• Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients

  2004cited by this paper
• Interaction Between Hypertension, apoE, and Cerebral White Matter Lesions

  2004cited by this paper
• Lewy body-related alpha-synucleinopathy in aging.

  2004cited by this paper
• Thinning of the cerebral cortex in aging.

  2004cited by this paper
• Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia

  2004cited by this paper
• Rivastigmine for dementia associated with Parkinson's disease.

  2004cited by this paper
• Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16‐month, comparative study

  2004cited by this paper
• White matter lesions are associated with cortical atrophy more than entorhinal and hippocampal atrophy.

  2004cited by this paper
• Executive dysfunction in Alzheimer disease.

  2004cited by this paper
• Rivastigmine in Frontotemporal Dementia

  2004cited by this paper
• Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy Bodies

  2004cited by this paper
• Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia.

  2004cited by this paper
• Dementia with Lewy bodies.

  2004cited by this paper
• Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype.

  2004cited by this paper
• Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease.

  2004cited by this paper
• Serum and CSF cholinesterase activity in various kinds of dementia

  2004cited by this paper
• Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release

  2004cited by this paper
• Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype

  2003cited by this paper
• Regulation of attention and response to therapy in dementia by butyrylcholinesterase.

  2003cited by this paper
• The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.

  2003cited by this paper
• What causes mental dysfunction in Parkinson's disease?

  2003cited by this paper
• Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.

  2003cited by this paper
• Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

  2003cited by this paper
• Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus

  2003cited by this paper
• Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies

  2003cited by this paper
• Neurobiology of butyrylcholinesterase

  2003cited by this paper
• Executive dysfunction and apathy predict functional impairment in Alzheimer disease.

  2003cited by this paper
• Cholinergic denervation in a pure multi-infarct state

  2003cited by this paper
• Silent brain infarcts and the risk of dementia and cognitive decline.

  2003cited by this paper
• Reality monitoring and visual hallucinations in Parkinson's disease.

  2003cited by this paper
• POTENTIAL LONG‐TERM EFFECTS OF RIVASTIGMINE ON DISEASE PROGRESSION MAY BE LINKED TO DRUG EFFECTS ON VASCULAR CHANGES IN ALZHEIMER BRAINS

  2003cited by this paper
• Ethics, public policy and behavioral genetics.

  2003cited by this paper
• Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease

  2003cited by this paper
• Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System

  2002cited by this paper
• Brain maturation may be arrested in chronic cocaine addicts.

  2002cited by this paper
• Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease

  2002cited by this paper
• Vascular cognitive impairment.

  2002cited by this paper
• Pathological Determinants of the Transition to Clinical Dementia in Alzheimer's Disease

  2002cited by this paper
• CADASIL: a Common Form of Hereditary Arteriopathy Causing Brain Infarcts and Dementia

  2002cited by this paper
• Rivastigmine in subcortical vascular dementia: an open 22-month study.

  2002cited by this paper
• Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease.

  2002cited by this paper
• Dopamine and the regulation of cognition and attention.

  2002cited by this paper
• Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association.

  2002cited by this paper
• Neuropsychiatric symptoms in the dementias

  2002cited by this paper
• Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank

  2002cited by this paper
• The Apathy Inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment

  2002cited by this paper
• Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease.

  2002cited by this paper
• Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease.

  2002cited by this paper
• Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.

  2002cited by this paper
• Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update.

  2002cited by this paper
• RIVASTIGMINE IN PATIENTS WITH ALZHEIMER'S DISEASE AND CONCURRENT HYPERTENSION

  2002cited by this paper
• Executive dysfunction in subcortical ischaemic vascular disease

  2002cited by this paper
• Subcortical dementia

  2002cited by this paper
• Subcortical Vascular Dementia

  2002cited by this paper
• The inflammatory reflex

  2002cited by this paper
• Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

  2002cited by this paper
• A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

  2001cited by this paper
• Donepezil, Rivastigmine, and Vitamin E in Alzheimer Disease: A Combined P300 Event-related Potentials/Neuropsychologic Evaluation over 6 Months

  2001cited by this paper
• Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

  2001cited by this paper
• Dementia in hereditary cerebral hemorrhage with amyloidosis‐Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles

  2001cited by this paper
• Basal ganglia dysfunction, working memory, and sentence comprehension in patients with Parkinson's disease.

  2001cited by this paper
• Memory failure has different mechanisms in subcortical stroke and Alzheimer's disease

  2000cited by this paper
• Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain.

  2000cited by this paper
• The frontal aging hypothesis evaluated

  2000cited by this paper
• The FAB: A frontal assessment battery at bedside

  2000cited by this paper
• Neuropsychology of infarctions in the thalamus: a review.

  2000cited by this paper
• Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity.

  2000cited by this paper
• Distinction Between Preclinical Alzheimer's Disease and Depression

  2000cited by this paper
• Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease

  2000cited by this paper
• Neuropathologic Substrates of Ischemic Vascular Dementia

  2000cited by this paper
• The Butyrylcholinesterase K‐Variant Shows Similar Cellular Protein Turnover and Quaternary Interaction to the Wild‐Type Enzyme

  2000cited by this paper
• An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors

  2000cited by this paper
• The role of cerebral ischemia in Alzheimer's disease.

  2000cited by this paper

• Therapeutic agents for Alzheimer’s disease: a critical appraisal

  2024cites this paper
• Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer’s Disease

  2024cites this paper
• Involvement of specific striatal subregion contributes to executive deficits in Alzheimer disease

  2023cites this paper
• Natural Inhibitors of Cholinesterases: Chemistry, Structure–Activity and Methods of Their Analysis

  2023cites this paper
• Design and Synthesis of Novel Dual Cholinesterase Inhibitors: In Vitro Inhibition Studies Supported with Molecular Docking

  2022cites this paper
• Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease.

  2022cites this paper
• Multitarget drugs as potential therapeutic agents for alzheimer’s disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors

  2022cites this paper
• Cholinesterase inhibitory activity of tinosporide and 8-hydroxytinosporide isolated from Tinospora cordifolia: In vitro and in silico studies targeting management of Alzheimer’s disease

  2021cites this paper
• Fucoxanthin has potential for therapeutic efficacy in neurodegenerative disorders by acting on multiple targets

  2021cites this paper
• Computational exploration and experimental validation to identify a dual inhibitor of cholinesterase and amyloid-beta for the treatment of Alzheimer’s disease

  2020cites this paper
• Effect of Prenatal Hypoxia on Activity of the Soluble Forms of Cholinesterases in Rat Brain Structures during Early Postnatal Ontogenesis

  2020cites this paper
• Indazolylketones as new multitarget cannabinoid drugs.

  2019cites this paper
• Novel Molecular Hybrids of N-Benzylpiperidine and 1,3,4-Oxadiazole as Multitargeted Therapeutics to Treat Alzheimer's Disease.

  2019cites this paper
• Executive Functions in Alzheimer Disease: A Systematic Review

  2019cites this paper
• Cholinesterase and Glycation Inhibition Assay of Several Metabolites Obtained from Plant and Fungi

  2019cites this paper
• Alzheimer’s Disease and Its Potential Alternative Therapeutics

  2019cites this paper
• Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer’s disease

  2018cites this paper
• Willughbeia cochinchinensis prevents scopolamine-induced deficits in memory, spatial learning, and object recognition in rodents.

  2018cites this paper
• Cognitive and Neuropsychiatric Features of Early Parkinson's Disease

  2017influential citation
• Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

  2017influential citation
• Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer ’ s and Parkinson ’ s Diseases

  2016cites this paper
• ASS 234 , As a New Multi-Target Directed Propargylamine for Alzheimer ’ s Disease Therapy

  2016cites this paper
• Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer’s Disease

  2016influential citation
• AChE and the amyloid precursor protein (APP) - Cross-talk in Alzheimer's disease.

  2016cites this paper
• Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

  2016cites this paper
• ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy

  2016cites this paper
• Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases

  2016cites this paper
• Effect of hypoxia on cholinesterase activity in rat sensorimotor cortex

  2015cites this paper
• Preparation, anticholinesterase activity, and docking study of new 2-butenediamide and oxalamide derivatives

  2015cites this paper
• Microwave-assisted synthesis, molecular docking, and cholinesterase inhibitory activities of new ethanediamide and 2-butenediamide analogues.

  2015cites this paper
• Understanding the Beneficial and Detrimental Effects of Donepezil and Rivastigmine to Improve their Therapeutic Value

  2015cites this paper
• Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.

  2014cites this paper
• Attention Disturbances Associated with Neurological Disease

  2014cites this paper
• Synthesis, docking and biological evaluation of oxamide and fumaramide analogs as potential AChE and BuChE inhibitors

  2014cites this paper
• CLINICAL TRIALS IN WHICH THE CDR SYSTEM HAS BEEN USED TO DETECT ENHANCEMENTS IN COGNITIVE FUNCTION

  2014cites this paper
• SPECT/PET Findings in Lewy Body Dementia

  2014cites this paper
• Developmental Adaptation of Central Nervous System to Extremely High Acetylcholine Levels

  2013cites this paper
• Multitarget cannabinoids as novel strategy for Alzheimer disease.

  2013cites this paper
• Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype

  2013cites this paper
• The multifactorial nature of Alzheimer's disease for developing potential therapeutics.

  2013cites this paper
• Human butyrylcholinesterase knock-out equivalent: Potential to assess role in Alzheimer's disease

  2012cites this paper
• A meta-analysis of voxel-based morphometry studies of white matter volume alterations in Alzheimer's disease.

  2012cites this paper
• Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort

  2012influential citation
• Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene.

  2012cites this paper
• Study of new propargylamine and donepezil-derived compounds as multitarget agents for the treatment of alzheimer’s disease

  2011cites this paper
• Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data

  2011cites this paper
• Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses

  2011cites this paper
• Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.

  2011cites this paper
• Parkinson's Disease Dementia and Potential Therapeutic Strategies

  2011cites this paper
• Should We Listen to People Affected by Dementia?

  2011cites this paper
• Evaluation of Dementia Rating Scales in Parkinson’s Disease Dementia

  2010cites this paper
• A novel effect of rivastigmine on pre‐synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease

  2010cites this paper
• Reviews: Effects of Transdermal Rivastigmine on ADAS-Cog Items in Mild-to-Moderate Alzheimer’s Disease

  2010cites this paper
• [Rivastigmine in the treatment of dementia: from the symptomatic effect to neuroprotection].

  2010cites this paper
• Effects of Oral Rivastigmine on Cognitive Domains in Mild-to-Moderate Alzheimer’s Disease

  2010cites this paper
• Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer's disease and dementia with Lewy bodies.

  2010cites this paper
• Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)

  2010cites this paper
• Theta power responses in mild Alzheimer’s disease during an auditory oddball paradigm: lack of theta enhancement during stimulus processing

  2010cites this paper
• Evaluating Rivastigmine in Mild-to-Moderate Parkinson’s Disease Dementia Using ADAS-Cog Items

  2010influential citation
• P2‐247: Effects of cholinesterase inhibition on brain white matter volume in mild Alzheimer's disease

  2009cites this paper
• Progressieve Supranucleaire Verlamming. Interventie middels acetylcholineesteraseremmer?

  2009cites this paper
• Comparison of EXIT-25 and the Frontal Assessment Battery for Evaluation of Executive Dysfunction in Patients Attending a Memory Clinic

  2009cites this paper
• Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias.

  2009influential citation
• [Progressive supranucleair palsy: acetylcholineeserase-inhibitor a possible therapy?].

  2009cites this paper
• Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment

  2009cites this paper
• Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story

  2009influential citation
• Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease.

  2009cites this paper
• The influence of fruit ripening on the phytochemical content and biological activity of Capsicum chinense Jacq. cv Habanero.

  2009cites this paper
• P4‐401: Identifying cognitive enhancement in man: Identifying efficacy in the dementias

  2008cites this paper
• Deterioro cognitivo asociado a la leucoaraiosis: fisiopatología, manifestaciones clínicas y tratamiento

  2008cites this paper
• A Review of the First Transdermal Treatment for Alzheimer’s Disease - The Rivastigmine Patch

  2008cites this paper
• The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.

  2008cites this paper
• [Cognitive impairment associated to leukoaraiosis: its pathophysiology, clinical manifestations and treatment].

  2008cites this paper
• Pharmacology of Rivastigmine Like other cholinesterase inhibitors, rivastigmine exerts its main action through the inhibition of cholinesterase enzymes. Reduction in the activity of these enzymes prevents the degradation of the neurotransmitter acetylcholine (ACh) after its release from the pre-syna

  2008cites this paper
• Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia

  2008cites this paper
• Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress

  2008cites this paper